Peripheral Neuropathy Market Report 2026

The peripheral neuropathy market size has grown rapidly in recent years. It will grow from $4.59 billion in 2025 to $5.17 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to high prevalence of diabetic neuropathy, rising chemotherapy use, limited targeted therapies, reliance on conventional analgesics, lack of early diagnosis tools.

The peripheral neuropathy market size is expected to see rapid growth in the next few years. It will grow to $7.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancements in nerve stimulation therapies, increasing adoption of physical therapy and non-pharmacological treatments, growing availability of topical and systemic medications, rising use of online pharmacies and telemedicine, expansion of specialized clinics and ambulatory centers. Major trends in the forecast period include increasing adoption of ai-based diagnostic tools for peripheral neuropathy, rising integration of big data and cloud solutions in patient monitoring, growing use of genomics and precision medicine for peripheral neuropathy treatment, increasing deployment of iot-enabled wearable devices for nerve health, rising implementation of industry 4.0 technologies in neuropathy treatment devices.

The rising prevalence of diabetes is expected to drive the growth of the peripheral neuropathy market in the coming years. Diabetes is a chronic condition marked by elevated blood glucose levels resulting from the body’s inability to produce sufficient insulin or effectively utilize it. The increasing incidence of diabetes is largely attributed to factors such as growing obesity rates, sedentary lifestyles, and aging populations. Diabetes can lead to peripheral neuropathy by causing nerve damage due to prolonged high blood sugar levels, resulting in symptoms such as pain, tingling, and numbness in the extremities. Proper blood sugar control is essential to prevent or delay the progression of this complication. For instance, in 2024, according to the International Diabetes Federation, a Belgium-based diabetes research organization, the number of adults aged 20 to 79 years living with diabetes worldwide is projected to rise substantially from approximately 589 million in 2024 to 853 million by 2050, reflecting a 45% increase. Therefore, the increasing prevalence of diabetes is contributing to the growth of the peripheral neuropathy market.

Major companies operating in the peripheral neuropathy market are concentrating on the development of advanced solutions, including point-of-care devices, to enhance the diagnosis and management of the condition. A point-of-care quantitative screening test for peripheral neuropathy is a diagnostic tool designed to quickly identify nerve damage in the extremities, particularly among individuals with diabetes. For example, in January 2023, NeuroMetrix Inc., a US-based non-invasive medical device manufacturer, introduced the DPNCheck 2 point-of-care device for detecting peripheral neuropathy. This device utilizes nerve conduction technology to identify systemic degeneration of peripheral nerves, which can result in debilitating conditions such as diabetic peripheral neuropathy (DPN). It enables rapid patient screening through quantitative measurement of peripheral nerve function, offering greater efficiency and accuracy compared to traditional methods such as monofilament and tuning fork tests.

In May 2024, Lexicon Pharmaceuticals, a US-based biopharmaceutical company focused on developing novel therapies for neuropathic pain, entered into a partnership with Medidata Solutions, Inc. to advance its Phase 2b PROGRESS study of LX9211 (pilavapadin) for the treatment of diabetic peripheral neuropathic pain (DPNP). This collaboration enhances the clinical development process of LX9211, a novel non-opioid AAK1 inhibitor, by utilizing Medidata’s decentralized clinical trial platform and real-time data capture capabilities, thereby improving patient experience and accelerating enrollment and trial execution. Medidata Solutions, Inc. is a US-based technology and software company that specializes in cloud-based solutions for clinical trials and life sciences research.

Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, Lexicon Pharmaceuticals, Johnson and Johnson, Teva Pharmaceutical Industries Ltd, Sanofi, GSK plc.

North America was the largest region in the peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peripheral neuropathy market by increasing costs of imported medications, nerve stimulators, and advanced diagnostic devices, affecting adoption in hospitals, clinics, and ambulatory centers, particularly in North America and Europe. The higher costs have slowed procurement in some regions, but they have also encouraged local manufacturing and development of cost-effective solutions, driving innovation in both pharmacological and non-pharmacological treatments.

The peripheral neuropathy market research report is one of a series of new reports that provides peripheral neuropathy market statistics, including peripheral neuropathy industry global market size, regional shares, competitors with a peripheral neuropathy market share, detailed peripheral neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral neuropathy industry. This peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peripheral neuropathy is a condition involving damage or impairment of the peripheral nerves, which are responsible for carrying signals between the central nervous system, including the brain and spinal cord, and the rest of the body. This condition can lead to a range of symptoms such as numbness, tingling sensations, weakness, and pain, most commonly affecting the hands and feet.

The primary types of peripheral neuropathy include chemotherapy-induced, diabetic, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-associated, and idiopathic neuropathy. Chemotherapy-induced neuropathy refers to side effects or conditions resulting from chemotherapy treatments. Diagnosis involves procedures such as blood tests, biopsies, imaging, and others, while treatment options include medications, antidepressants, anti-seizure drugs, pain relievers, topical treatments, therapies, nerve stimulation, plasma exchange, physical therapy, and others. The key end users comprise hospitals, clinics, and ambulatory centers.

The peripheral neuropathy market consists of revenues earned by entities by providing services such as neurological evaluation, pain management, physical therapy, occupational therapy, podiatry services, orthopedic support, nutritional counseling, psychological support, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral neuropathy market also includes sales of pain relief creams, orthopedic shoes, compression socks, tens devices, foot care kits, braces and supports, nutritional supplements, mobility aids, and assistive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.